These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16428243)

  • 21. Tamoxifen therapy for patients with breast cancer.
    Neven P; Joensuu H; Osborne K; Cardoso F; Loibl S; Linn S; Goldhirsch A; Ortmann O; Senn HJ; Hayes DF
    Lancet; 2013 Jun; 381(9883):2078. PubMed ID: 23769226
    [No Abstract]   [Full Text] [Related]  

  • 22. Can endocrine treatment for hormone-positive premenopausal women with early breast cancer replace adjuvant chemotherapy?
    Malayeri R
    J Clin Oncol; 2003 Jun; 21(12):2444-5; author reply 2446-7. PubMed ID: 12805348
    [No Abstract]   [Full Text] [Related]  

  • 23. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
    Buzdar AU
    Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges in the endocrine management of breast cancer.
    Mouridsen HT; Rose C; Brodie AH; Smith IE
    Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving adherence to endocrine therapies: the role of advanced practice nurses.
    Kelly A; Agius CR
    Oncology (Williston Park); 2006 Sep; 20(10 Suppl Nurse Ed):50-4; discussion 55. PubMed ID: 18153980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [For how long should breast cancer patients take Tamoxifen? The International Program ATLAS will answer this question].
    Semiglazov VF
    Vopr Onkol; 1998; 44(4):373-7. PubMed ID: 9807196
    [No Abstract]   [Full Text] [Related]  

  • 27. POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen.
    Cohen AL; Factor RE; Mooney K; Salama ME; Wade M; Serpico V; Ostrander E; Nelson E; Porretta J; Matsen C; Bernard P; Boucher K; Neumayer L
    Breast; 2017 Feb; 31():219-223. PubMed ID: 27915204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant endocrine therapy in breast cancer.
    Abrial C; Mouret-Reynier MA; Curé H; Feillel V; Leheurteur M; Lemery S; Le Bouëdec G; Durando X; Dauplat J; Chollet P
    Breast; 2006 Feb; 15(1):9-19. PubMed ID: 16230013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended adjuvant tamoxifen for breast cancer--a new era?
    Powles TJ
    Lancet; 2013 Mar; 381(9869):782-3. PubMed ID: 23219287
    [No Abstract]   [Full Text] [Related]  

  • 30. The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review.
    Rossi L; McCartney A; De Santo I; Risi E; Moretti E; Malorni L; Biganzoli L; Di Leo A
    Cancer Treat Rev; 2019 Mar; 74():29-34. PubMed ID: 30708267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
    Taguchi T; Noguchi S
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1465-74. PubMed ID: 19755814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eligibility, compliance and persistence of sequential therapy with aromatase inhibitors following 2-3 years of tamoxifen in endocrine adjuvant breast cancer therapy.
    Kilic N; Myrick ME; Schmid SM; Gueth U
    Oncology; 2011; 81(3-4):151-7. PubMed ID: 22041855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
    Ward JH
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case for Tamoxifen with ovarian function suppression.
    Kopparthy P; Daily K
    Breast Cancer Res Treat; 2020 Aug; 183(1):241-242. PubMed ID: 32601972
    [No Abstract]   [Full Text] [Related]  

  • 36. [Current adjuvant endocrine treatment of breast cancer].
    Dedes KJ; Gabriel N; Fink D
    Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Adjuvant for breast cancer chemo-endocrine therapy].
    Taguchi T
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):453-67. PubMed ID: 9530350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stopping tamoxifen after 5 years of therapy for early breast cancer: does it alter quality of life?
    Hall PS; Walkington JP; Cameron DA
    Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):652. PubMed ID: 21703830
    [No Abstract]   [Full Text] [Related]  

  • 39. Delayed adjuvant tamoxifen in postmenopausal women with axillary node-negative breast cancer: mortality over 10 years.
    Love RR; Olsen MR; Havighurst TC
    J Natl Cancer Inst; 1999 Jul; 91(13):1167-8. PubMed ID: 10393732
    [No Abstract]   [Full Text] [Related]  

  • 40. Five years of tamoxifen--or more?
    Peto R
    J Natl Cancer Inst; 1996 Dec; 88(24):1791-3. PubMed ID: 8961965
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.